Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 6/20 | 0.46 |
| ▸ | DBH | P09172 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 2/20 | 0.42 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771857 | 1.00 | MAPT (0.47) | MAPTRAB9ARECQLMITFNPSR1 | |
| SCHEMBL6767061 | 0.83 | TUBB1 (0.56) | MAPTRAB9ANPSR1MAOADBH | |
| SCHEMBL6767057 | 0.83 | TUBB1 (0.56) | MAPTRAB9ANPSR1MAOADBH | |
| SCHEMBL6770393 | 0.83 | MAOB (0.60) | MAPTMAOBMAOAALDH1A1GPR35 | |
| SCHEMBL6770402 | 0.83 | MAOB (0.60) | MAPTMAOBMAOAALDH1A1GPR35 | |
| SCHEMBL6776282 | 0.80 | BACE1 (0.47) | MAPTRAB9ARECQLMITFNPSR1 | |
| SCHEMBL6776289 | 0.80 | BACE1 (0.47) | MAPTRAB9ARECQLMITFNPSR1 | |
| SCHEMBL7659900 | 0.76 | MAOB (0.56) | MAPTRAB9ANPSR1MAOBMAOA | |
| SCHEMBL6770296 | 0.74 | APP (0.61) | MAPTRAB9AMAOBNPC1 | |
| SCHEMBL6770302 | 0.74 | APP (0.61) | MAPTRAB9AMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683095-B2 | ANTICARCINOGENIC AGENTS; ANTIPROLIFERATION AGENTS | LG LIFE SCIENCES LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | LG LIFE SCIENCES LTD. (KR) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | CDK4, CDK3, CDK6 | MAPT 2270/4885RAB9A 4302/4885RECQL 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.